1. Home
  2. Category
  3. Diagnosis and Screening

Treatment Decision Making

Profession

Financial Toxicity: Management as an Adverse Effect of Cancer Treatment

Kristen L. Fessele
CJON 2017, 21(6), 762-764 DOI: 10.1188/17.CJON.762-764
Along with many physical and emotional adverse effects associated with cancer therapy, attention has been directed to defining and identifying interventions to manage financial strain that can occur because of high medical payments and reduced income from employment interruption. Nurses can support...
0
No votes yet
Read this Article
Essentials

Percutaneous Nephrostomy Infusion: Nursing Considerations for Treatment of Upper Urinary Tract Urothelial Carcinoma

Eryn Draganski
Ellen Sterman
Kathy Morris
CJON 2017, 21(6), 759-761 DOI: 10.1188/17.CJON.759-761
An intrarenal approach using a percutaneous nephrostomy tube is a novel method to deliver chemotherapy and biotherapy to patients with upper urinary tract urothelial carcinoma. A paucity of evidence exists regarding basic nursing implications for this unique treatment option. This column will...
0
No votes yet
Read this Article
CNE Article

Pharmacogenomics: Principles and Relevance to Oncology Nursing

Crystal H. Dodson
CJON 2017, 21(6), 739-745 DOI: 10.1188/17.CJON.739-745
Background: Pharmacogenomics is the fastest growing field in precision medicine. Based on current use, oncology encompasses the largest share of the precision medicine market, necessitating that oncology nurses understand the principles of pharmacogenomics and how it affects clinical practice...
5
Average: 5 (1 vote)
Read this Article
Article

Initial Efficacy Testing of an Autobiographical Memory Intervention on Advance Care Planning for Patients With Terminal Cancer

Cheryl Brohard
ONF 2017, 44(6), 751-763 DOI: 10.1188/17.ONF.751-763
Purpose/Objectives: To test the efficacy of a novel intervention to facilitate advance care planning. Design: Exploratory, quasiexperimental pilot study with two independent groups. Setting: A large hospice located in the southwestern United States. Sample: A convenience sample of 50 participants...
0
No votes yet
Read this Article
Article

Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Heather Brumbaugh Paradis
Debbie Alter
Diane Llerandi
CJON 2017, 21(5), 604-610 DOI: 10.1188/17.CJON.604-610
Background: Venetoclax (Venclexta™) is a potent, selective, orally available, small-molecule B-cell lymphoma 2 inhibitor that achieves response rates of about 80% and has an acceptable safety profile for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Objectives: The aim...
0
No votes yet
Read this Article

Questions, Concerns or Requests

We're just a click away for assistance.